Windtree Therapeutics (WINT) stock price, revenue, and financials

Windtree Therapeutics market cap is $138.4 m, and annual revenue was $1.79 m in FY 2018

$138.4 M

WINT Mkt cap, 08-Jan-2020
Windtree Therapeutics Net income (Q3, 2019)-7.1 M
Windtree Therapeutics EBIT (Q3, 2019)-7.2 M
Windtree Therapeutics Cash, 30-Sept-20194.4 M
Windtree Therapeutics EV142.7 M

Windtree Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

2.8m987.0k2.0m1.5m1.8m

Cost of goods sold

517.0k2.7m929.0k

Gross profit

164.0k58.0k

Gross profit Margin, %

6%6%

R&D expense

17.2m21.6m27.7m26.7m28.9m31.7m17.4m10.6m

General and administrative expense

7.9m16.4m16.7m16.7m11.0m8.4m6.7m7.4m

Operating expense total

25.1m38.0m44.4m43.4m39.9m40.1m24.0m18.0m

EBIT

(24.5m)(37.8m)(44.5m)(43.3m)(39.8m)(38.0m)(22.5m)(16.2m)

EBIT margin, %

(1526%)(4036%)(1863%)(1518%)(906%)

Interest expense

20.0k13.0k4.1m4.3m

Interest income

6.0k3.0k6.0k237.0k18.0k12.0k15.0k

Income tax expense

Net Income

(21.0m)(37.3m)(45.2m)(44.1m)(55.2m)(39.5m)(18.4m)(20.5m)

Windtree Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

21.5m15.4m54.8m46.0m36.1m26.4m31.3m21.2m75.9m65.6m54.9m35.6m26.1m46.3m29.4m20.3m12.4m8.0m2.5m1.8m1.9m638.0k640.0k2.1m6.1m4.4m

Accounts Receivable

41.0k22.0k

Prepaid Expenses

299.0k327.0k393.0k433.0k1.2m621.0k618.0k418.0k702.0k443.0k357.0k576.0k571.0k433.0k500.0k454.0k210.0k392.0k318.0k248.0k129.0k397.0k399.0k502.0k1.2m826.0k

Inventories

105.0k128.0k36.0k117.0k173.0k443.0k429.0k

Current Assets

21.8m15.7m55.2m46.5m37.4m27.0m31.9m21.7m76.8m66.5m55.7m36.2m26.7m48.7m31.3m21.9m13.7m9.5m3.9m3.1m2.0m1.0m1.0m16.1m9.9m5.3m

PP&E

2.8m2.6m2.1m2.2m2.0m1.7m1.5m1.4m2.0m2.2m1.8m1.7m1.2m1.2m1.1m1.0m1.0m1.0m977.0k930.0k844.0k804.0k764.0k826.0k893.0k877.0k

Goodwill

15.7m15.7m15.7m

Total Assets

25.2m18.7m57.7m49.2m39.8m29.2m33.9m23.6m79.5m69.5m58.3m38.1m28.2m52.7m34.7m25.0m16.4m11.7m5.8m4.7m3.0m2.0m1.9m111.6m105.2m100.6m

Accounts Payable

2.0m1.4m1.3m1.3m208.0k1.8m1.9m1.5m2.6m1.5m1.4m702.0k2.3m2.5m5.5m7.7m5.2m2.3m2.8m3.8m4.7m4.3m4.5m1.4m724.0k607.0k

Short-term debt

93.0k74.0k67.0k67.0k68.0k70.0k71.0k72.0k74.0k30.1m30.1m30.0m30.0m25.0m25.0m12.5m12.5m15.1m2.5m2.5m4.3m7.5m8.0m7.8m

Current Liabilities

15.1m13.1m14.6m12.6m15.9m13.0m10.3m11.3m11.1m10.9m9.4m9.3m9.8m9.8m14.6m15.1m14.1m24.8m25.4m29.5m15.7m15.2m18.1m17.0m15.5m16.3m

Long-term debt

260.0k242.0k205.0k186.0k167.0k6.1m6.2m6.4m48.8m49.3m49.8m20.9m21.5m25.0m25.0m25.0m25.0m12.5m12.5m12.5m1.3m1.1m953.0k

Total Debt

353.0k316.0k272.0k253.0k235.0k6.2m6.3m6.5m48.9m79.4m79.9m50.9m51.5m50.0m25.0m25.0m25.0m25.0m25.0m27.6m2.5m2.5m4.3m8.7m9.1m8.7m

Total Liabilities

16.0m14.0m15.5m13.5m16.7m19.7m17.1m18.2m30.7m30.3m29.3m30.3m31.3m34.8m39.7m40.2m39.3m37.5m38.0m42.1m31.0m30.4m33.3m48.6m47.0m47.6m

Common Stock

24.0k24.0k43.0k43.0k44.0k44.0k55.0k55.0k85.0k85.0k85.0k86.0k86.0k112.0k8.0k8.0k8.0k10.0k11.0k16.0k3.0k4.0k4.0k32.0k32.0k32.0k

Preferred Stock

Additional Paid-in Capital

400.6m400.9m452.7m453.3m454.0m459.8m475.8m476.7m543.2m544.2m545.3m547.0m547.4m589.9m591.1m591.5m592.3m604.7m605.0m605.2m616.6m619.3m620.3m730.2m731.9m733.8m

Retained Earnings

(388.4m)(393.1m)(407.4m)(414.6m)(427.9m)(447.4m)(456.0m)(468.2m)(491.4m)(502.0m)(513.4m)(536.2m)(547.5m)(569.1m)(593.1m)(603.7m)(612.1m)(627.4m)(634.1m)(639.6m)(641.6m)(644.7m)(648.6m)(664.2m)(670.6m)(677.7m)

Total Equity

9.2m4.7m42.2m35.7m23.1m9.5m16.8m5.5m48.8m39.2m29.0m7.8m(3.1m)17.9m(5.0m)(15.2m)(22.8m)(25.8m)(32.2m)(37.4m)(28.1m)(28.4m)(31.3m)63.0m58.3m53.1m

Debt to Equity Ratio

-5 x-1.6 x-1.1 x

Debt to Assets Ratio

0.7 x1 x1.5 x

Financial Leverage

2.7 x4 x1.4 x1.4 x1.7 x3.1 x2 x4.3 x1.6 x1.8 x2 x4.9 x-9.2 x2.9 x-7 x-1.6 x-0.7 x-0.5 x-0.2 x-0.1 x-0.1 x-0.1 x-0.1 x1.8 x1.8 x1.9 x

Windtree Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(21.0m)(37.3m)(45.2m)(44.1m)(55.2m)(39.5m)(18.4m)(20.5m)

Depreciation and Amortization

1.2m1.2m707.0k818.0k712.0k192.0k1.0m

Accounts Receivable

(67.0k)67.0k

Inventories

195.0k(431.0k)(1.8m)201.0k

Accounts Payable

(574.0k)55.0k267.0k(1.1m)2.9m2.4m997.0k

Cash From Operating Activities

(22.7m)(32.9m)(40.5m)(41.2m)(33.5m)(21.0m)(15.8m)

Purchases of PP&E

(106.0k)(636.0k)(608.0k)(780.0k)(458.0k)(24.0k)

Cash From Investing Activities

(106.0k)(636.0k)(608.0k)(780.0k)(188.0k)(24.0k)(13.7m)

Short-term Borrowings

(160.0k)

Long-term Borrowings

(75.0k)(80.0k)(5.1m)(2.5m)

Cash From Financing Activities

22.8m50.2m100.5m377.0k27.7m17.3m38.7m

Net Change in Cash

(22.0k)16.7m59.4m(41.6m)(6.0m)(3.8m)9.3m

Interest Paid

(20.0k)13.0k920.0k2.6m1.5m1.1m288.0k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(11.9m)(16.7m)(10.0m)(17.2m)(30.5m)(12.6m)(21.3m)(33.5m)(11.5m)(22.1m)(33.4m)(12.2m)(23.5m)(45.1m)(13.9m)(24.5m)(32.9m)(8.7m)(15.5m)(20.9m)(4.5m)(7.6m)(11.5m)(6.5m)(13.0m)(20.1m)

Depreciation and Amortization

644.0k954.0k288.0k576.0k855.0k197.0k364.0k537.0k149.0k371.0k577.0k425.0k561.0k626.0k76.0k140.0k199.0k56.0k101.0k147.0k41.0k82.0k303.0k105.0k231.0k305.0k

Accounts Receivable

67.0k26.0k45.0k

Inventories

105.0k128.0k195.0k159.0k78.0k(1.1m)(2.2m)(2.3m)201.0k201.0k201.0k

Accounts Payable

301.0k(299.0k)228.0k224.0k(903.0k)659.0k753.0k323.0k1.1m74.0k(30.0k)352.0k2.0m2.1m2.2m4.5m2.0m1.7m2.2m3.2m1.6m1.2m1.5m(2.0m)(2.7m)(2.8m)

Cash From Operating Activities

(11.1m)(17.2m)(5.5m)(14.0m)(23.8m)(10.2m)(20.4m)(30.4m)(10.3m)(20.3m)(31.1m)(8.7m)(18.3m)(25.9m)(9.2m)(18.3m)(26.6m)(7.3m)(12.9m)(16.2m)(2.5m)(6.3m)(9.6m)(8.8m)(15.4m)(19.2m)

Purchases of PP&E

(26.0k)(88.0k)(138.0k)(518.0k)(593.0k)(120.0k)(120.0k)(204.0k)(497.0k)(883.0k)(679.0k)(448.0k)(503.0k)(508.0k)(137.0k)(149.0k)(193.0k)(20.0k)(24.0k)(24.0k)(74.0k)(226.0k)(129.0k)

Cash From Investing Activities

(26.0k)(88.0k)(138.0k)(518.0k)(593.0k)(120.0k)(120.0k)(204.0k)(497.0k)(883.0k)(679.0k)(448.0k)(243.0k)(248.0k)(137.0k)(149.0k)(166.0k)(20.0k)(24.0k)(24.0k)9.0k9.0k425.0k11.3m13.9m

Short-term Borrowings

(447.0k)(474.0k)(820.0k)

Long-term Borrowings

(20.0k)(39.0k)(57.0k)(18.0k)(37.0k)(56.0k)(19.0k)(39.0k)(59.0k)(20.0k)(41.0k)(5.1m)

Cash From Financing Activities

22.5m22.5m50.3m50.3m50.3m9.8m24.9m24.9m435.0k415.0k398.0k(20.0k)(41.0k)27.7m69.0k471.0k9.8m9.8m12.4m2.5m5.0m8.3m(598.0k)(625.0k)(971.0k)

Net Change in Cash

11.3m5.2m44.6m35.8m25.9m(522.0k)4.4m(5.7m)(10.3m)(20.7m)(31.4m)(9.1m)(18.6m)1.6m(9.3m)(18.4m)(26.3m)2.4m(3.1m)(3.8m)(46.0k)(1.3m)(1.3m)(9.1m)(5.1m)(6.8m)

Interest Paid

11.0k16.0k(4.0k)7.0k10.0k116.0k336.0k559.0k649.0k1.3m2.0m649.0k1.3m1.5m22.0k61.0k280.0k259.0k514.0k514.0k

Windtree Therapeutics Ratios

USDY, 2019

EV/EBIT

-19.9 x

EV/CFO

-7.4 x

Financial Leverage

1.9 x